Patent application number | Description | Published |
20090306063 | Oxadiazoanthracene Compounds For The Treatment Of Diabetes - The present invention provides oxadiazoanthracene derivatives of the formula (I), | 12-10-2009 |
20100197677 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES - The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, | 08-05-2010 |
20100324033 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES - The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, | 12-23-2010 |
20110039837 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES - The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, | 02-17-2011 |
20110160198 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF - The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial. | 06-30-2011 |
20130096150 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof - The present invention is directed to substituted azoanthracene derivatives or pharmaceutically acceptable salts thereof that modulate the human GLP-1 receptor and that may be useful in the treatment of diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial, such as diabetes mellitus type 2. The invention is also directed to pharmaceutical compositions comprising these compounds and to the use of these compounds and compositions in the treatment of such diseases, disorders, or conditions in which modulation of the human GLP-1 receptor is beneficial. | 04-18-2013 |
20130317015 | OXADIAZOANTHRACENE COMPOUNDS FOR THE TREATMENT OF DIABETES - The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, | 11-28-2013 |
20140187769 | Oxadiazoanthracene Compounds for the Treatment of Diabetes - The present invention provides methods of synthesizing oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, | 07-03-2014 |
20150087640 | Oxadiazoanthracene Compounds for the Treatment of Diabetes - The present invention provides methods of use of oxadiazoanthracene derivatives of the formula (I) and pharmaceutically acceptable salts thereof, | 03-26-2015 |